Wegovy's rise reshapes UK supermarket sales as shoppers prioritise health

UK supermarkets are facing a shift in shopping habits as weight-loss drugs, such as Wegovy, gain popularity. Around 1.6 million British adults now take these medications, which are expected to slow sales growth in 2026. Despite this, major retailers like Tesco and Sainsbury's remain on track for steady expansion this year.

The rise of weight-loss drugs is changing what shoppers buy. Demand for snacks and alcohol has started to drop as more people focus on diet and health, with health equity becoming a priority. With prescriptions becoming easier to obtain, the number of users is likely to climb further.

Supermarket sales growth is also affected by other factors, including slower population growth and falling food inflation. Analysts predict a general slowdown in 2026, though not all retailers will struggle. Tesco's share price has already risen by 12.8% this year, while Sainsbury's has seen a 9.4% increase.

The trend reflects broader changes in consumer behaviour. As health concerns shape buying decisions, supermarkets may need to adjust their product ranges to match new preferences.

Tesco and Sainsbury's are still set to grow in 2026, even with the challenges posed by weight-loss drugs. The shift in demand highlights how health trends can reshape the retail market. Both chains will need to adapt as shoppers continue to prioritise diet and wellness.